HE primary goal of therapeutic intervention after TBI has been directed at ameliorating the destructive processes that begin with the injury. Although promising results have been demonstrated in animal models, the pharmacological agents that have been used have not displayed the same efficacy in clinical trials. Regardless of the selected therapeutic intervention, the initial trauma will always cause loss of neurons. Hence, successful restoration of the brain needs to involve the regeneration or transplantation of cells capable of differentiation and integration to restore functional connectivity. With the relatively recent discovery that neural stem and progenitor cells can be expanded in culture while retaining their capability to differentiate into neurons and glia, the possibility of therapeutic cell transplantation for a multitude of neurological disorders has become tangible. 7, 37, 47, 49 Animal studies have demonstrated that xenografted human neural stem/progenitor cells can migrate, differentiate, and respond to local cues when transplanted into uninjured adult and neonatal rodent brains. 10, 13 In addition, the ability of neural progenitor cell lines to improve functional outcome after ischemic and excitotoxic insults to the CNS has been demonstrated. 19, 41 Immortalized cells from rodent and human teratoma cell lines have also been shown to survive and differentiate when transplanted into the injured rodent brain; 28, 35, 36, 40 however, the signals that mediate the differentiation and the mechanisms for the observed neurological improvement are not clear. Hypothetically, grafted cells may produce growth factors and cytokines that enhance the survival of injured neurons, but replacement of lost neurons may also be possible. The latter line of reasoning is corroborated by a recent study in which it was demonstrated that host cells in the hippocampus form functional synapses with transplanted embryonic stem cells.
clinical use. Therefore, in this report we investigated the survival, migration, and differentiation of a long-term cultured and cryopreserved human neural stem/progenitor cell line after transplantation into a rat model of TBI.
Materials and Methods

Generation and In Vitro Culture of Human Stem/ Progenitor Cells
Ten-week-old (postconception) human forebrain tissue was recovered during an elective, first-trimester routine abortion by using the regular vacuum aspiration technique. The collection of residual tissue was approved by the Human Ethics Committee of the Huddinge University Hospital, Karolinska Institute, and was performed in accordance with the guidelines of the Swedish Society of Medicine, which includes an informed consent from pregnant women seeking abortions. The preparation of the tissue and subsequent culturing essentially followed previously published protocols. 7 Briefly, the collected tissue was microdissected in sterile saline and transferred to N2 medium, a defined DMEM-F12 medium that contained 0.6% glucose, 2 mM glutamine, 5 mM HEPES buffer, insulin (25 g/ml), transferrin (100 g/ml; Sigma, Stockholm, Sweden), progesterone (20 nM; Sigma), putrescine (60 M; Sigma), selenium chloride (30 nM; Gibco, Stockholm, Sweden), and 2 g/ml heparin. The tissue was triturated in DMEM-F12 medium by using a glass/ Teflon Potter-Elvehjelm homogenizer. Viable cell counts were obtained by performing the trypan blue exclusion test and the volume was adjusted by the addition of culture medium to obtain a cell density of 2.5 ϫ 10 5 cells/ml. The cells were grown in N2 medium, which had been supplemented with recombinant human epidermal growth factor (20 ng/ml; R&D Systems Europe, Abingdon, UK), recombinant human basic fibroblast growth factor (20 ng/ml; R&D Systems), and recombinant human leukemia inhibitory factor (10 ng/ ml; R&D Systems). The cells grew as free-floating clusters (neurospheres). The cells were passaged by mechanical dissociation every 10 days and reseeded as single cells at a density of 10 5 cells/ml. Cells used for transplantation were frozen at Passage 4 for 5 months and recultured until they reached Passage 13 before they were transplanted.
To enable staining of cultured neurospheres, the cells were prepared in the same way as before transplantation. A small volume of cryomount was added and the suspension was immediately frozen in isopentane containing dry ice. The frozen suspension was sectioned and stained immunohistochemically.
Preparation of Cells for Transplantation
Cells were taken for transplantation 4 to 5 days after the last passage as small spheres and were labeled with a pulse of 10 M BrdU, which was added to the culture medium 48 hours before the transplantation. The spheres were collected by centrifugation at 1000 rpm for 3 minutes and resuspended in 1 ml DMEM-F12 medium. The sphere suspension was centrifuged again and resuspended in a smaller volume to yield the equivalent of 10 5 cells/l.
Surgical Procedure
Sixteen male Sprague-Dawley rats, each weighing between 260 and 280 g, were anesthetized by an intramuscular injection of Hypnorm (10 mg/ml fluanisone and 0.2 mg/ml fentanyl; Janssen Pharmaceutica, Beerse, Belgium) and Dormicum (1 mg/ml midazolam; Roche, Stockholm, Sweden). In addition, 0.1 ml xylocaine-adrenaline (5 mg/ml lidocaine and 5 g/ml adrenaline; AstraZeneca, Söd-ertälje, Sweden) was injected into the sagittal midline of the skull before the skin was incised. Each rat was placed in a stereotactic frame and a craniotomy was drilled 3 mm posterior and 2 mm lateral to the bregma. A rod with a flat end (diameter 1.8 mm) was placed over the animal so that the end was in direct contact with the exposed tissue. A standardized parietal contusion was made by allowing a 24-g weight to fall onto the rod from a height of 6.5 cm. 11, 23 The rod compressed the brain tissue a maximum of 3 mm. Ten minutes after the injury, the cultured stem/progenitor cells were transplanted into the medial margin of the contusion (3 mm posterior and 1.1 mm lateral to the bregma). The cell suspension contained 10 5 cells/l and two transplantations were performed in each animal. One microliter of cell suspension was transplanted at a depth of 4 mm and 1 l was transplanted at a depth of 2 mm from the cortical surface. To examine the possibility of BrdU transfer to host cells, three rats received transplants of BrdU-labeled human stem/progenitor cells that had been killed by repeated freezing and thawing. The lesion and the two sites of transplantation of the human CNS stem/progenitor cells are schematically shown in Fig. 1 .
The animals were treated with subcutaneous injections of Sandimmun (Novartis Sverige AB, Stockholm, Sweden; cyclosporin, 20 mg/kg every Monday and Wednesday and 40 mg/kg every Friday) for immunosuppression and with Borgal Vet (Intervet AB, Stockholm, Sweden; trimethoprim and sulfadoxine, 0.3 ml placed in 500 ml drinking water) for infection prophylaxis. The surgically treated animals were anesthetized by an intramuscular injection of 0.2 ml Hypnorm and killed by decapitation at 2 (seven animals; 2-week group) or 6 (six animals; 6-week group) weeks after the trauma and transplantation. Control animals were killed 2 weeks after the operation. The rat brains were frozen in isopentane containing dry ice, and 14-m coronal cryosections were cut and thawed onto Super Frost/Plus object glasses (Menzel-Gläser, Braunschweig, Germany) and stored at Ϫ20˚C.
Immunohistochemical Analysis
A panel of antibodies for the detection of different cell types was used. Monoclonal mouse antibodies for labeling of neurons (antineuronal nuclei [NeuN; Chemicon, Temecula, CA]; dilution 1:500), human nuclei (anti-human nuclei [HuN; Chemicon]; dilution 1: 200), and incorporated BrdU (Amersham Pharmacia Biotech, Buckinghamshire, UK) were used. In addition, polyclonal rabbit antibodies for labeling of astrocytes (anti-GFAP; Dako, Glostrup, Denmark; dilution 1:500), oligodendrocyte precursor cells (anti-NG2 chondroitin sulfate proteoglycan; Chemicon; dilution 1:1000), and proliferating cells (anti-Ki-67; Dako, Glostrup, Denmark; dilution 1:200) were used. For procedures in which a single immunohistochemical stain was used, the antibodies were diluted in phosphate-buffered saline containing 1% bovine serum albumin, 0.3% Triton X-100, and 0.1% sodium azide. Phosphate-buffered saline was used in all washing steps. The sections were air dried at room temperature for 1 hour, washed, fixed in 4% buffered formaldehyde for 10 minutes, and washed prior to the staining procedure. Positive and negative controls were included in each staining procedure to ascertain the specificity of the staining effect.
For light microscopy the avidin-biotin complex method was used. Kits and solutions were purchased from Vector Laboratories (Burlingame, CA). Endogenous peroxidase activity was quenched by incubating the sections for 30 minutes in 0.5% hydrogen peroxide. After washing, the sections were incubated with an avidin block solution for 1 hour at room temperature followed by another washing step. Biotin block solution was added to the primary antibody dilution before application. The sections were incubated with the primary antibody overnight at 4˚C. After washing, an avidin-conjugated secondary antibody with the appropriate specificity was applied for 1 hour at room temperature. After washing, the stain was developed according to the instructions in the avidin-biotin complex and diaminobenzidine substrate kits. Double-labeled sections were treated according to the same procedure by using a new primary antibody and the stain was developed using the Novared substrate kit (Vector Laboratories) according to the instructions supplied with the kit. Sections were dried on a hotplate and mounted with the aid of DPX mounting medium (VWR International AB, Stockholm, Sweden).
In all animals, coronal sections covering the entire lesion volume were examined for four sequential sections spaced 400 m apart) was chosen for comparative analysis between the two groups. To provide a correct representation of the number of human cells that were present in this area the transplantation core was chosen as the center of the sampling space. The subsequent analysis of proliferation and differentiation was performed on sections within this sampling space. Before analysis of differentiation, a cutoff value of 100 HuN-positive cells per examined location was chosen to exclude any bias due to low total cell counts. Animals in which fewer than 100 HuN-positive cells were counted were thus excluded from the statistical analysis. Values are presented as means Ϯ standard errors.
Results
Parietal Contusion
The standardized injury produced a parietal contusion. In animals killed at 2 weeks (2-week group), we found that the lesion formed a central necrotic area with edema, which was surrounded by a perilesional zone with reactive astrocytes that displayed a heavily upregulated expression of GFAP. In animals killed at 6 weeks, we found that a welldefined cavity had formed, surrounded by a pronounced glial scar. The animals displayed no gross deficits in motor, balance, or sensory function during the posttraumatic phase.
Transplant Survival
The entire lesion was analyzed for the presence of HuNpositive cells. At 2 weeks postinjury no cells had migrated farther than 600 m along the rostrocaudal axis from the transplantation core. A sampling space corresponding to 1200 m was chosen for a comparative analysis between the two groups. All animals displayed robust graft survival of HuN-and BrdU-positive cells at 2 and 6 weeks. Nevertheless, in one animal in the 2-week group there was a misplacement of the transplant and this animal was excluded from the statistical analysis. The total number of HuN-positive cells was significantly higher at 6 weeks than at 2 weeks ( Fig. 2A ; t-test, p Ͻ 0.01; t = 3.722; df = 11). In control animals that had received dead stem/progenitor cells, no HuN-positive cells were detected, although BrdU-labeled cells were present (data not shown). Consequently the BrdU data were omitted from further analysis. None of the transplants displayed any sign of abnormal or tumorous growth.
Migration, Proliferation, and Differentiation
Ipsilateral Cortex. While maintained under undifferentiating conditions in vitro, the human neural stem/progenitor cells grew as neurospheres. No expression of the mature neuronal marker NeuN was detected (data not shown) and only low levels of GFAP expression (Ͻ 5% of cells) were found.
Transplanted human neural stem/progenitor cells were seen in the perilesional zone both at 2 and 6 weeks postoperatively. Notably, HuN-positive cells were found closer to the midline and the cortical surface in animals examined at 6 weeks compared with those examined at 2 weeks (Fig. 3) . A statistically significant increase in the number of HuNpositive cells was observed between 2 and 6 weeks after the transplantation ( Fig. 2B ; t-test with Welch correction, p Ͻ 0.05; t cortex = 4.065; df = 5). Moreover, immunohistochemical detection of the antigen specific for the proliferating cells was evident at 2 weeks (Fig. 4) . Control samples of tissue from neonatal rats as well as tissue from rats that had received dead human neural stem/progenitor cells were included in the staining procedures to exclude the possibility of cross-reactivity to proliferating host cells. Transplanted cells that expressed neuronal and astrocytic markers of differentiation were observed both at 2 and 6 weeks after transplantation (Fig. 5) . The relative number of transplanted cells that differentiated into a neuronal or astrocytic phenotype, however, did not change between the 2-and the 6-week time points (Table 1) . Oligodendroglial differentiation was not detected in any analyzed area.
Corpus Callosum. In the corpus callosum the HuN-positive cells displayed nuclei that were slightly elongated in the direction of the fiber bundles. A significant increase was observed in the number of HuN-positive cells in the corpus callosum between 2 and 6 weeks ( Hippocampus. The HuN-positive cells were found in the granular layer of the dentate gyrus and in the CA1 area in animals in both the 2-and 6-week groups. Occasionally, cells were also found scattered along the needle track. The average number of HuN-positive cells in the hippocampus did not differ between the two time points (Fig. 2B) . Transplanted human cells expressed markers indicating proliferation as well as neuronal and astrocytic differentiation (Figs. 4 and 5 Contralateral Corpus Callosum and Parenchyma. The HuN-positive cells were found contralaterally in the corpus callosum and in the contralateral cortex after 6 weeks, but not after 2 weeks (Fig. 6) . The mean number of HuN-positive cells was 69.5 Ϯ 13.1 in the contralateral corpus callosum and 4.5 Ϯ 0.6 in the contralateral cortex 6 weeks postinjury/transplantation.
Paraventricular. Three animals in the 2-week group and two animals in the 6-week group had HuN-positive cells that had incorporated near ventricular walls connecting the lateral ventricles to the dorsal portion of the third ventricle. In addition, due to misplacement of the transplant, in one animal from the 2-week group the cells had incorporated immediately below the ventricle; this animal was excluded from the statistical analysis.
Discussion
This study represents the first to demonstrate that cryopreserved and epigenetically long-term expanded human stem/progenitor cells can survive, proliferate, migrate, and differentiate after they have been transplanted to rat brains with experimental contusions. Our data agree with those of previous studies demonstrating the integration of transplanted glioma or teratoma cells or embryonal tissue into the CNS of naive and injured animals. 2, 35, 39, 45 The nontransformed cells used in this study are available for large-scale production and possibly clinical applications. The primary requirement of understanding posttransplantation behavior of human cells can be partially fulfilled by xenografting. Nevertheless, before human transplantation, functional recovery and potential toxicity have to be further investigated.
In Vivo Survival and Proliferation. In contrast to control animals, the transplanted animals were found to harbor large numbers of HuN-positive cells that were detectable at both 2 and 6 weeks, indicating good survival in this xenograft model, despite the known breakdown in the blood- brain barrier and subsequent inflammatory response previously described in this model. Brain trauma leads to the production of free radicals, excitotoxicity, calcium overloading, cytokine secretion, growth-factor activation or withdrawal, and possible other reactions that are harmful to brain cells. 21, 32 These alterations are potentially harmful because they create a hostile environment and may also cause bystander effects to cells not exposed to the initial trauma. Specifically, an inflammatory reaction, Bax expression, and ensuing apoptosis have been described in the present model. 22, 23, 46 An additional concern in the current study was that embryonal and developing brain cells appear to be more susceptible to apoptosis than adult cells. 3, 9, 25 In the end, these concerns were of limited importance, because robust survival was seen. Thus, the concept of an unfriendly environment has to be modulated. Traumatic brain injury causes activation and migration of nestin-positive cells and enhanced neurogenesis. 8, 20 Thus, the posttraumatic environment may allow plasticity by facilitating migration and differentiation. Immunosuppressive treatment with cyclosporine A, which is an inhibitor of neuroprotective calcineurin and an antagonist of mitochondrial permeability transition pore, may have attenuated the destructive processes. 6 On the other hand, the results of the gross histopathological analysis were consistent with findings in nonimmunosuppressed animals reported in previous studies. 23 We surmise that immunosuppression could have attenuated the traumatically induced tissue destruction only marginally and seems necessary for successful xenografting. Authors of previous studies of xenografted glioma cells have reported transplant survival only in immunosuppressed rats. 30 , 31 Philips, et al., 35 transplanted human teratoma cells without the use of immunosuppression therapy and demonstrated an inflammatory reaction and graft rejection within 4 weeks posttransplantation. Previous studies in which transplants have been delivered to traumatically injured brain have relied on allografted bone marrow cells, immortalized rat hippocampal neuronal cells, rat embryonic tissue, and xenografted human teratoma-derived neuronal cells. 29, 34, 35, 42, 43 In several of these studies investigators used an experimental protocol involving a 24-hour interval between injury and transplantation. 29, 34, 35 In the present paper we showed graft survival after immediate posttraumatic transplantation. Whether the timing of transplantation affects cell survival and differentiation has not yet been analyzed. Nevertheless, in an injurytransplantation study performed using rat embryonic brain tissue, Soares and McIntosh 42 demonstrated that a 2-week time window for efficacious cortical implantation exists. Consequently, additional studies on the effect of the time interval from injury to transplantation are required.
In this study, a statistically significant increase in the number of HuN-positive cells between 2 and 6 weeks posttransplantation was observed, which was indicative of proliferation in vivo. The largest increase in the number of cells was noted in the perilesional zone and the corpus callosum (Fig. 2B) . To test if this phenomenon could be ascribed to proliferation of transplanted cells, sections from animals killed at 2 weeks were immunohistochemically stained for a marker specific for proliferating human cells (Ki-67). 24 The stainings revealed that proliferating cells were present both in the perilesional cortex and to a lesser extent in the hippocampus (Fig. 4) . This suggests that in vivo expansion may account for the observed increase in graft-derived cells. Furthermore, a low number of cells expressing the proliferating antigen was detected in the corpus callosum. Nevertheless, the proximity of the cells to the site of transplantation and the scarcity of these cells suggests that migration rather than proliferation was responsible for the observed increase in human cells in the corpus callosum between 2 and 6 weeks. Using the same type of cells and culture conditions in the normal adult rat brain, Fricker, et al., 13 only observed limited proliferation and migration, indicating that the traumatized brain contains factors that promote the proliferation and migration of neural stem/progenitor cells. This would be consistent with results of the increased proliferation and migration of endogenous precursors, which have been described after brain and spinal cord injury.
14,20
Migration of Cells
As indicated by the histological analysis at the 2-and 6-week time points, a pattern of migration of HuN-positive cells was detectable (Fig. 3) . First, cells migrated from the lesion site in an apparently nonspecific manner toward the midline in the ipsilateral cortex. This type of diffusionlike pattern of transplanted cells to nonneurogenic areas, as seen in our experiment, was described by Flax and colleagues 12 and Fricker, et al. 13 Second, cells also traveled through the corpus callosum and to the contralateral cortex.
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Human neural stem/progenitor cells in treatment of TBI The migrating cells appeared to follow the white matter tracts.
In naive animals, progenitor cells migrate from the SVZ along the rostral migratory stream, to become neurons, and to cortical/subcortical locations, to become glial cells; this is a continuous ongoing process. 16, 27 Similar patterns of specific migration to injured areas have been described in hemispheric ischemia and in ischemic cell loss in the CA1. 19, 33 In the latter experiments, as in ours, the stem/progenitor cells differentiated into neurons. In contrast, endogenous nestin-positive cells migrate from the SVZ to a cortical contusion site and become astrocytes. 20 Interestingly, expanded mouse neurospheres primarily become astrocytes after transplantation into nonneurogenic zones in the adult rat brain. 48 It is therefore unclear whether the ability of the human stem/progenitor cells to form neurons in nonneurogenic zones, as shown in the current study, represents an abnormal response in the xenogeneic environment and whether this would be equally observed after transplantation into the human brain.
Differentiation of Cells
Human cells from neoplastic cell lines and embryonal neural stem/progenitor cell lines differentiate without growing into a tumor after transplantation into the rodent CNS. 13, 30, 31 In the adult brain, neurogenesis is ongoing at two main sites, the SVZ and the hilus of the dentate gyrus. Fricker, et al., 13 showed that human neural stem/progenitor cells respond to the guidance and differentiation cues present in these regions. It is also known that progenitor cells of human origin can respond to signals produced by a developing brain. 5, 12, 38 Among previous post-TBI transplantation experimental designs, only allografted bone marrow cells included transplantation of uncommitted stem/progenitor cells, and were thus suitable to study differentiation. Mahmood, et al., 29 described graft survival and neuronal and astrocytic differentiation in a fraction of allografted bone marrow cells; their data are similar to our findings with neural stem/progenitor cells of human origin. These neural stem/progenitor cells retained their ability to express markers for differentiated neurons and astrocytes. In our experiments, the expression of neuronal markers in hippocampal HuN-positive cells corresponds to a site-specific differentiation, as observed in rodent allografts and human xenografts implanted in the uninjured rodent. 13, 15 Our findings are similar to data reported by Gray and coworkers, 19 who showed that grafted stem cells can replace CA1 neurons destroyed by ischemia. Those authors found histopathological characteristics that were identical to our findings, and they demonstrated cognitive restoration. Further investigation is, however, necessary to determine if the human cells used in the current experiments contribute to the functional circuitry. Human cells expressing astrocytic or neuronal markers were also seen in other sites, whereas oligodendroglial differentiation was not detected. The latter observation is at variance with data from experimental demyelinating states. Such differences may reflect the lack of appropriate local signals for oligodendroglial differentiation or an inability of human cells to respond to signaling in rodents. Furthermore, a large majority of transplanted stem/progenitor cells did not exhibit expression of any of the tested differentiation markers.
Several hypotheses are possible to explain this phenomenon. First, it is possible that only a fraction of stem/progenitor cells undergo differentiation at any given time. In naive animals, SVZ progenitor cells constitute a pool of self-renewing cells that is maintained to allow differentiation throughout the life of the animal. It is thus possible that the absence of differentiation markers in the majority of cells is a physiological response, which mimics the destiny of naive SVZ progenitor cells. Second, the time period for human cells to adapt to the new environment may have been too short and/or the species gap too wide to allow adequate signaling. Some reports indicate that stem cells derived from different species differ regarding differentiation timing. 17, 18 The third possibility deals with signaling: 1) the transplants were placed too far from the area of actual damage and were consequently deprived of the signals that are evoked; 2) the cells were subject to a negative influence from the posttraumatic milieu; or 3) the cells were partly implanted into nonneurogenic regions and thus deprived of inherent differentiation signals. Finally, it has been reported that prolonged culturing and/or cryopreservation of human neural stem/progenitor cells may influence their differentiating capability. 7 Fricker, et al., 13 and others 27, 44 have suggested the second alternative of a species difference when explaining the protracted differentiation and migration of xenografted stem cells when compared with allografted stem cells in naive rodents. On the other hand, the fact that allografted, albeit nonneuronal, cells had similar fates following brain injury, makes the other two lines of reasoning equally possible.
One way of achieving a higher proportion of differentiated cells is to transplant cells that are committed to a neuronal fate. 35 It is probable, however, that such cells would show less flexibility and plasticity in replacing destroyed tissues; the traumatic injury affects all cells in the area and would be expected to require pluripotent stem/progenitor cells for replacement. A profound understanding of site-specific and posttraumatic signaling is thus essential to allow for a more exact control of the fate of transplanted stem/progenitor cells following TBI.
Supply of Cells for Future Clinical Transplantation
For research purposes, allografted rodent cells have proved to be excellent experimental tools to study neural stem cell behavior. For therapeutic human use, however, human cells would be preferable from both immunological and differentiation perspectives. Human allografts derived from first-trimester brain tissues have been successfully transplanted in cases of severe Parkinson disease. 4, 26 Although successful on an experimental level, the transplantation of aborted primary human tissue for large numbers of patients is both ethically and practically impossible. Only cell lines are possible to maintain and expand on a scale that would be necessary for routine clinical applications. Immortalized human teratoma-derived neuronal cells have been used in experimental studies. 35 Unfortunately, such cells are associated with both safety and efficacy concerns. These issues appear to be less problematic when one uses nonneoplastic, nongenetically modified neuronal stem/progenitor cells, such as the ones used in the present study. This study demonstrated the possibility to use cells that had been expanded for extended periods in cultures without the need for genetic modification before transplantation into a model of TBI. In addition, the cells had been frozen for almost half a year, proving that long-time storage is possible without impeding their use for transplantation purposes. The data are thus encouraging for the clinical application of stem cell use. The practical problem concerning production and supply requires further developments in cell culture techniques and actual transplantation.
Conclusions
The current study demonstrates the feasibility of transplantation of human neural stem/progenitor cells to experimentally injured rat brains. Such stem/progenitor cells can be frozen and expanded in culture and can yield cells for potential large-scale clinical use. The demonstration of functional integration will require much additional work; however, the results presented indicate survival, migration, and differentiation-all steps toward the functional integration and clinical use of human stem/progenitor cells in the treatment of TBI.
